Role of 68Ga-FAPI PET/CT in Patients in Whom 18F-FDG PET/CT Has Been Found to be Questionable or Inconclusive Due to Oncological Pathology (FAPI-MN-2020)
To evaluate the accuracy of [68Ga]Ga-FAPI PET/CT in detecting the presence of oncological disease in patients with inconclusive or equivocal findings after the standard clinical/diagnostic flow chart: [18F]F-FDG PET/CT imaging not able to solve the clinical doubt or equivocal/inconclusive for the evaluation of oncological disease.
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
Studied population Approximately 200 patients will be enrolled with inconclusive or equivocal findings after the standard clinical/diagnostic flow chart: [18F]F-FDG PET/CT imaging not able to solve the clinical doubt or equivocal/inconclusive for the evaluation of oncological disease.
Patients enrolled must satisfy all the inclusion criteria and must sign an informed consent. The informed consent will be signed by the patient in the nuclear medicine department before the performance of any experimental procedure.
Primary aim
Secondary aim
To evaluate the accuracy of [68Ga]Ga-FAPI PET/CT in detecting the presence of oncological disease in patients with inconclusive or equivocal findings after the standard clinical/diagnostic flow chart: [18F]F-FDG PET/CT imaging not able to solve the clinical doubt or equivocal/inconclusive for the evaluation of oncological disease.
To evaluate accuracy, sensitivity and specificity of [68Ga]Ga-FAPI PET/CT and [18F]F-FDG PET/CT (standard examination currently performed in several oncological settings) in detecting the presence of oncological disease in patients with inconclusive or equivocal findings after the standard clinical/diagnostic flow chart: [18F]F-FDG PET/CT imaging not able to solve the clinical doubt or equivocal/inconclusive for the evaluation of oncological disease.
Primary endpoint accuracy of [68Ga]Ga-FAPI PET/CT in detecting the presence of oncological disease in patients with inconclusive or equivocal findings after the standard clinical/diagnostic flow chart: [18F]F-FDG PET/CT imaging not able to solve the clinical doubt or equivocal/inconclusive for the evaluation of oncological disease.
Secondary enpoint accuracy, sensitivity and specificity of [68Ga]Ga-FAPI PET/CT and [18F]F-FDG PET/CT (standard examination currently performed in several oncological settings) in detecting the presence of oncological disease in patients with inconclusive or equivocal findings after the standard clinical/diagnostic flow chart: [18F]F-FDG PET/CT imaging not able to solve the clinical doubt or equivocal/inconclusive for the evaluation of oncological disease.
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Italy
-
Bologna, Italy, 이탈리아, 40138
- IRCCS Azienda Ospedaliero Universitaria di Bologna
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Inclusion criteria • Age ≥18 years old
- Both sexes
- Patients with oncological disease suspicion/ new diagnosis or with a previously treated tumour (with previous treatments performed at least 3 months before enrollment) and with an inconclusive or equivocal [18F]F-FDG PET/CT, especially cases of:
-
Suspect primary or secondary (lymph-nodes or distant metastases) lesions with absent/faint FDG uptake or low TBR;
-
And/or suspect primary or secondary (lymph-nodes or distant metastases) lesions in a site of phisiological FDG uptake (such as brain or liver) or in sites in which FDG has a low sensitivity (i.e. peritoneal carcinomatosis, esophageal-gastro-intestinal tract);
-
And/or low glucose metabolism tumour hystotypes (i.e. renal clear cell carcinoma, mucinous mammary tumours, well differentiated HCC);
-
And/or differential diagnosis between tumour and inflammation (i.e. determining lymph-nodes benign or malignant nature in head/neck cancers, differential diagnosis between inflammation or malignant tissue in sarcomas).
- Signed informed consent
Exclusion Criteria: Exclusion Criteria • Pregnancy. In order to rule out pregnancy a β-hCG blood test will be performed in women of childbearing age.
- Breastfeeding
- Patients in emergency situations or unfit to plead.
- History of allergic reactions or hypersensitivity to the active substance, to any of the excipients, or to any of the components of the radiolabeled radiopharmaceutical
- Contraindication to PET / CT examination for patients unable to perform PET due to weight, claustrophobia or the inability to remain still for the duration of the examination
- Participation in a clinical trial in which an investigational drug was administered within 30 days or 5 half-lives before the study drug
- Patients with impaired renal function;
- Patients with impaired liver function;
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 특수 증상
- 할당: 무작위화되지 않음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
diagnostic performance
기간: 9 years
|
sensitivity, specificity, AUC, detection rate, accuracy, positive and negative predictive value compared to the reference standard. |
9 years
|
공동 작업자 및 조사자
간행물 및 유용한 링크
일반 간행물
- Giesel FL, Kratochwil C, Lindner T, Marschalek MM, Loktev A, Lehnert W, Debus J, Jager D, Flechsig P, Altmann A, Mier W, Haberkorn U. 68Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers. J Nucl Med. 2019 Mar;60(3):386-392. doi: 10.2967/jnumed.118.215913. Epub 2018 Aug 2.
- Chen H, Pang Y, Wu J, Zhao L, Hao B, Wu J, Wei J, Wu S, Zhao L, Luo Z, Lin X, Xie C, Sun L, Lin Q, Wu H. Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging. 2020 Jul;47(8):1820-1832. doi: 10.1007/s00259-020-04769-z. Epub 2020 Mar 28.
- Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, Adeberg S, Rathke H, Rohrich M, Winter H, Plinkert PK, Marme F, Lang M, Kauczor HU, Jager D, Debus J, Haberkorn U, Giesel FL. 68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. J Nucl Med. 2019 Jun;60(6):801-805. doi: 10.2967/jnumed.119.227967. Epub 2019 Apr 6.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- FAPI-MN-2020
- 2020-005549-17 (EudraCT 번호)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .